Axotomy of the rat optic nerve leads to apoptotic cell death present beyond the time-point of detectable transcription of retinal ganglion cells (RGCs). We have used adenoviral of the p35 transgene, we conclude that apoptosis has been vectors to transduce RGCs from the cut optic nerve stump, efficiently inhibited. In addition, we observed that transduca paradigm in which only those neurons are transduced tion with two control vectors without a transgene in E1 also which are directly affected by the axonal lesion. Transresulted in a minor but significant RGC rescue, implicating genes encoded by the vectors were p35 and CrmA, which neuroprotective effects due to adenoviral transduction are potent intracellular anti-apoptotic proteins. We found itself. This system will be useful in dissecting the pathways that p35, but not CrmA exerted significant rescue effects leading to neuronal cell death after axonal lesions and in on RGCs 14 days after axotomy. Expression of the transthe evaluation of the important question whether the genes was driven by the murine CMV (MCMV) promoter. cellular suicide program can be reverted to survival by The respective mRNAs were detectable 7 days but not 14 therapeutic gene delivery. days after transduction. Since surviving RGCs were
Introduction
Programmed cell death (apoptosis) is an important process in the development as well as in the maintenance of metazoan organisms. 1, 2 If the apoptotic program is blocked, for example, in cells with DNA damage, malignant cell proliferation may be the consequence, since potentially dangerous cells are not properly eliminated. 3 On the other hand, if pathological or inappropriate apoptosis occurs, especially in nondividing, terminally differentiated tissue like the CNS, cell loss leads to degenerative disorders. Apoptosis has been claimed to be responsible for neuronal cell loss after ischemia, 4 stroke, 5, 6 spinal muscular atrophy 7 and Alzheimer's disease, 8, 9 although the exact contribution of the cellular suicide program in these disorders remains to be evaluated. Moreover, apoptosis is induced as a secondary phenomenon in several neuronal populations in the CNS after axonal lesions, for example, in traumatic injuries. 10, 11 The apoptotic program is executed by a family of specialized proteases, called caspases. 1, 12 These proteins are present in cells as inactive zymogens which are activated through proapoptotic signals. Generally, initiator caspases mediate the activation of effector caspases, which in turn cleave specific target proteins. Initiator caspases may Receptor-mediated cell death has also been described for developing CNS neurons, 14, 15 however, the recruitment of caspases to the p75NTR receptor remains to be proven. Changes in the integrity of the mitochondria, especially the release of cytochrome c, is also a potent trigger for caspase activation. 16 Both pathways can finally converge on the activation of common effector caspases as caspase 3 (CPP32).
Since survival of lesioned neurons is a fundamental requirement for any regenerative therapy it is of great clinical relevance to be able to interfere with the caspasemediated death program. To this end, we used a well established model system of axonal injury and apoptosis, the transection of the optic nerve. Cutting the rat optic nerve results in apoptotic cell death of more than 80% of the retinal ganglion cells, which are the only retinal cells projecting an axon into the optic nerve, 14 days after the lesion has been set. [17] [18] [19] In recent studies we have successfully used the intraocular injection of recombinant BDNF peptide along with free radical scavenger 20 and inhibitory peptides for caspases 21 to prevent apoptosis of RGCs. However, due to the short half-life of the peptides repeated injections were necessary, finally resulting in overall damage of the retina. In this study we alternatively used adenoviral vectors, which are retrogradely transported in neurons, 22, 23 to introduce well characterized anti-apoptotic proteins into RGCs by transduction of the axons at the optic nerve stump. In contrast to intraocular or subretinal vector administration, only those neurons can be transduced which are directly affected by the lesion.
The baculovirus protein p35 has been shown to inhibit a broad spectrum of initiator and effector caspases, 24, 25 making it a powerful tool in the inhibition of apoptosis. P35 serves as a substrate for caspases and is cleaved by them. The cowpox virus CrmA protein also inhibits caspases, but has a more limited inhibitory spectrum, mainly targeting caspase 1 (ICE) and caspase 8 (Flice), which is death receptor associated. 26 We show here for the first time that p35 but not CrmA exhibited substantial anti-apoptotic effects in axotomized neurons in vivo. Transgene expression from the Ad vectors was driven by the mouse CMV (MCMV) promoter, 27 which has not been used for studies in the CNS before. We found only short-term expression driven by this promoter, with no detectable mRNA expression 14 days after transduction. However, significant amounts of RGCs which had survived axotomy due to vector transduction were still present at that time-point, indicating that the apoptotic execution program had been efficiently blocked in the transduced cells.
Results

Vectors
In this study we used adenoviral vectors coding for well characterized anti-apoptotic proteins, p35 and CrmA, to inhibit apoptosis in axotomized retinal ganglion cells. As controls two vectors were constructed which did not carry a transgene in the E1 region. One carried a promoter directly followed by a polyadenylation site, the other had no functional elements in E1. All vectors had the wild-type E3 region retained in the viral DNA ( Figure  1a) . In order to quantify expression from the recombinant Ad.crmA and Ad.p35 vectors, MRC5 fibroblasts were transduced with identical multiplicities of infection (MOI) and protein lysates were probed with an anti-HA antibody. This epitope tag was added to the transgenes to allow the application of the same antibody to compare protein production quantitatively. We found that substantially more protein was generated from the Ad.crmA vector than from the Ad.p35 vector, although both transgenes had identical Kozak sequences and polyadenylation sites (Figure 1b) .
Cell rescue
Recombinant adenoviral vectors were used to transduce axotomized retinal ganglion cells from the transected optic nerve stump. Note that no injections into the nerve stump were performed, in order to avoid any transduction of cells other than RGCs which might occur by penetrating retinal tissue with the needle tip. The timespan for application of the vectors in a drop of PBS/10% glycerol was kept to a minimum (5 min) to avoid possible ischemic influences due to distortion of retinal blood supply.
After axotomy and viral transduction, retinal ganglion cells were labeled by administration of the retrogradely transported fluorescent tracer Fast Blue (FB), which was also applied at the nerve stump. The number of surviving cells was counted 14 days after axotomy. Labeled cells with normal morphology were considered to be nonapoptotic. Figure 2 shows representative areas of retinas transduced with the control vector Ad.dE1 and the Ad.p35 vector, respectively, both used at titers of 3 × 10 A more detailed analysis of the survival promoting effects of the various vectors is given in Figure 3 . Since about 350 RGCs/mm 2 survive at 14 days after axotomy without any treatment or PBS/10% glycerol application, the number of FB-labeled cells counted in the respective groups was subtracted by 350 to give the amount of cells surviving due to viral transduction.
In a first set of experiments we used the Ad.p35, Ad.crmA and Ad.mcmv vectors with a titer of approximately 3 × 10 7 p.f.u./l (total volume 5 l, applied for 5 min) to transduce the nerve stump. We found that application of all three vectors resulted in elevated numbers of surviving RGCs. About 550 labeled cells per mm 2 were counted in these groups as compared with about 350 labeled cells per mm 2 in the no vector control ( Figure 3 , light shaded bars). Thus, about 200 cells/mm 2 survived due to the adenoviral transductions. This was a significant rescue effect but there was no significant difference in the Ad.p35 and Ad.crmA groups as compared with the Ad.mcmv control vector group.
In order to evaluate whether a titer-dependent rescue effect of the various vectors could be achieved we set up a second set of experiments, using a 10 times higher amount of recombinant Ad vectors (about 3 × 10 8 p.f.u./l in a 5 l drop). In addition, we constructed another control vector without functional elements in E1 (Ad.dE1). In contrast to the Ad.mcmv vector this construct does not have a promoter in E1 and thus allows evaluation of whether the presence of a strong promoter in this position has any influence on the rescue rates of the vectors.
In these experiments application of the Ad.p35 vector resulted in a pronounced increase in cell survival (Figures 2 and 3, dark shaded bars; P = 0.01 when compared with the Ad.p35 low titer administration and the Ad.dE1 and Ad.mcmv vectors high titer administrations). Ad.p35 transduction led to the survival of 400 RGCs/mm 2 , which is 2.5 times the value of Ad.mcmv and four times the value of Ad.dE1. The Ad.crmA again showed elevated but not significant cell rescue when compared with the control vectors. Again, both control vectors were capable of rescuing RGCs from cell death. While Ad.dE1 showed a clear tendency towards cell resue, Ad.mcmv showed significantly higher numbers of surviving cells when compared with the no vector control group.
Expression control
Since the crmA and p35 proteins were tagged with the HA epitope we used an antibody against this tag to detect expression of these proteins from the adenoviral vectors. We were not able to detect the tagged proteins or their cleavage products either in Western blots of extracts of transduced retinas or by immunohistochemical staining of retinal cryosections, although in control experiments we were able to detect the proteins in lysates from transduced MRC-5 cells (Figure 1b) . Available anti-bodies against p35 and crmA themselves (generous gifts from J Wilson, Dept of Endomology, University of Georgia, Athens, GA, USA and J Yuan, Dept of Cell Biology, Harvard Medical School, Boston, MA, USA) also failed to give consistent results in immunohistochemical stainings. Also, Northern blotting was unsuccessful in detecting the p35 and crmA mRNAs in RNA preparations from transduced retinas, presumably because RGCs make up only a small portion of all retinal cells (data not shown).
Thus, a semi-quantitative RT-PCR approach was performed to evaluate the duration of transgene expression in the ganglion cells. Reverse transcription of RNA extracted from transduced retinas was performed by using specific primers for both, the transgene (either p35 or crmA) and G3PDH as internal standard. To achieve maximum sensitivity, we set up a nested PCR approach. The amount of primers used was adjusted in a way to allow for a nested PCR approach without generating excessive amounts of product from the standard, G3PDH. Under the conditions applied, no amplification products were visible after the first PCR reactions. In the second, nested, PCR reaction we found a strong amplification signal both for p35 and crmA when using RNA extracted from retinas 7 days after transduction. Virtually no product was detectable in RNA extracted 14 days after transduction (Figure 4a ). To demonstrate unambigously that the RT-PCR fragments obtained were generated from the p35 and crmA mRNAs, they were probed with p35 and crmA-specific oligonucleotides along with corresponding RT-PCR fragments obtained from Ad.p35 and Ad.crmA transduced MRC-5 cells (Figure 4b ).
Transduction with Ad.lacZ
We have found that transduction with the Ad.p35 vector did not result in a specific cell rescue at low titer but that a 10-fold increase of the number of applied vector particles resulted in a doubling of surviving cells as compared with control vectors. In addition, the Ad.p35 vector produced less of the transgene's protein than the Ad.crmA vector. Thus, it may be assumed that more viral particles must transduce an individual axon to produce enough p35 to inhibit activated caspases. To evaluate whether individual axons can take up various amounts of virus we constructed an Ad.lacZ vector, which has the same viral backbone as all other vectors used in this study, however, transgene expression was driven by a human CMV promoter/enhancer. Staining for ␤-galactosidase activity with X-gal should give a direct measure of the amount of protein produced in individual cells.
We used a titer of 3 × 10 8 /l to transduce RGCs from the nerve stump under the same experimental conditions as described above and stained whole mount retinas for ␤-galactosidase activity 5 days later. We found (1) RGCs to be the only ␤-galactosidase positive cells throughout all layers of the whole mount specimen ( Figure 5A ), and (2) pronounced differences in the staining intensities of individual ganglion cells were obvious ( Figure 5B ). Some cells were heavily stained while many others were barely visible, suggesting large differences in the uptake of the virus by individual axons. It is also important to note that only relatively few RGCs were stained. We found no more than 30-50 clearly visible stained cells/mm 2 , indicating that only a subset of RGCs can be transduced in the short time the nerve stump is exposed to the viral suspension. However, due to the large number of cells stained only weakly we assume that we could not detect all transduced cells. The low number of stained cells was independent of the method used for fixation and permeabilization of the whole mount retinas.
Discussion
Since loss of CNS neurons after trauma, ischemia or in neurodegenerative disorders is irreversible, it is of great clinical interest to reduce this cell loss as much as possible. Several recent studies using viral vector systems have shown promising results. Adenoviral vectors encoding secreted neurotrophic factors such as GDNF in models of Parkinson's disease, 28, 29 CNTF in motor neuron lesion 30 and BDNF in optic nerve transsection 31 have been shown to exert neuroprotective effects. The BDNF vector was injected intraocularly, transducing mainly Muller glia. 31 However, the mechanisms by which neurotrophins protect neurons from apoptosis are indirect and remain to be elucidated. Intracellular anti-apoptotic proteins (Bcl-2 and NAIP) have been used in models of ischemia. In these studies 32, 33 vectors were injected in distinct brain areas, transducing glia as well as neurons, and neuroprotective effects were determined 2-5 days after lesion. Longer lasting neuroprotective effects have been observed so far only in axotomized motorneurons, which have been transduced by injection into the nerve stump with neurotrophin coding vectors. 30 In this study, we have evaluated a model for protecting CNS neurons from apoptosis after a defined axonal lesion which combines several useful features: (1) for anatomical reasons only those neurons (RGCs) can be transduced which are directly affected by the axonal lesion; (2) the lesion can be set reproducibly; (3) the transgenes used (p35, CrmA) have well defined anti-apoptotic properties, 25 ,26 but have not been used for in vivo application in CNS neurons before; (4) the 14 days period between axotomy/transduction and quantification of surviving cells should be long enough to allow for a prediction whether apoptosis can be efficiently inhibited, since the majority of cells die around days 5-7; 19 and (5) the bloodbrain barrier is not distorted by the application of the vectors, leaving the retina in its immune-privileged state. 34 The fact that Ad.p35 transduction shows a potent neuroprotective effect on axotomized RGCs is further direct proof that these cells are undergoing apoptosis after axonal injury. P35 has been shown to inhibit caspases 1 (ICE), 3 (CPP32), 6 (Mch2), 7 (Mch3), 8 (Flice) and 10 (Mch4), all at similar K i values. 25 Thus, this protein is a nonspecific but potent caspase inhibitor and might be a valuable tool to block acute apoptotic processes, eg after traumatic injuries. CrmA shows a much higher selectivity for caspase inhibition than p35, with high affinity to caspases 1 and 8 but low affinity to caspases 3, 6 and 7. 26 Because caspase 1 does not directly contribute to neuronal apoptosis, 35 a specific neuroprotective effect of the Ad.crmA vector would have suggested a participation of caspase 8 in cell death caused by optic nerve transsection. Since caspase 8 is a death receptor-associated protein, our finding that no neuroprotective effect was observed argues against a role of receptor-mediated apoptosis in axotomized neurons. Caspase 3, which has recently been shown to be activated in axotomized RGCs, 36 is not only activated through death receptors but also through caspase 9. The latter is actived by cytochrome c release from mitochondria and subsequent Apaf1 oligomerization.
37,38
The protective effect of the Ad.p35 vector may thus be explained by caspase 3 inhibition and argues for a pathway mediated by mitochondria in axotomized RGCs. P35 may also have direct inhibitory effects on caspase 9 itself. Further experiments employing more specific inhibitors of mitochondria-mediated apoptosis (such as Bcl-X L ) will have to prove that this proposed death cascade is activated in axotomized RGCs. The failure of the Ad.crmA vector to show specific neuroprotective effects was not due to the presence of the HA tag, since the same vector exhibited potent inhibition of caspase activation in cultured cerebellar granule cells after medium switch to low potassium. Also, after transduction of cerebellar granule cells, both the Ad.p35 and the Ad.crmA vector showed inhibition of caspase activity in measurements of DEVD-amc cleavage (Gerhard, Kü gler and Schulz, unpublished results).
Our results strongly support that apoptosis in the axotomized RGCs has been efficiently inhibited. We detected transgene expression 7 days after transduction, but virtually no expression 14 days after transduction, although a sensitive nested PCR system was used to amplify the respective mRNAs. This held true for both the Ad.p35 and the Ad.crmA vector. However, significantly more labeled RGCs were present 14 days after axotomy in the Ad.p35 high-titer group when compared with the control and Ad.crmA groups. This indicated that although no further p35 mRNA was transcribed, RGCs were viable at this time-point due to viral transduction and transient p35 production. It remains to be evaluated whether this is a true reversal of the apoptotic programme to survival or just a postponing of cell death. It is tempting to speculate, however, that the unknown signal initiating apoptosis in axotomized RGCs is of only short duration. Thus, if no further proapoptotic signal stimulates the cellular death machinery, then its inhibition for several days might be sufficient to overcome the death programme. Even in the case that the death programme has not been completely terminated, its delay might offer the opportunity for additional therapeutic strategies.
The fact that surviving cells are present beyond the time-point of detectable p35 and crmA expression strongly argues against the assumption that immunological clearance of transduced cells is responsible for the loss of transcription of the transgenes. This is in accordance with recent findings suggesting that the cytotoxic T cell response to adenoviral vector transduction in the brain is not sufficient to eliminate transduced cells 39 unless a peripheral T cell stimulation to the vector occurs. 40 In our system no other tissue but the nerve stump and the dura were exposed to the viral particles, except for a little spillage to intraorbital tissues. It is more likely that silencing of the MCMC promoter occurred as it has been described for CMV and RSV viral promoters in organotypical cultures or cell culture. 41, 42 In no case did we observe damages of the retinal structure following transduction of the nerve stump as seen after intraocular injection of a ␤-galactosidase coding vector. 43 Due to this detrimental effect of the Ad.lacZ vector it was not used as a control for the therapeutic Ad.p35 and Ad.crmA vectors in the present study.
We used two control vectors in this study, which do not code for a transgene in E1. The Ad.mcmv was used to determine whether the sole presence of a strong promoter in E1 might lead to the activation of potentially protective or detrimental adenoviral genes. Application of the Ad.mcmv vector resulted in statistically significant rescue rates at both titers used. Although the Ad.dE1 vector showed no significant rescue rate in the statistical tests applied it showed a clear tendency towards cell rescue. This makes it difficult to assign any rescue effect to the MCMV promoter itself or to transcription of adenoviral genes due to the presence of this promoter.
The mechanism of rescue of axotomized neurons from apoptotic cell death by 'null' vectors remains to be elucidated. Either the stimulation of the retrograde transport in the axons by the applied viral particles activates some cellular survival promoting factors or leaky transcription from the viral backbone results in the expression of protective factors. An alternative explanation may be the secretion of cytokines from adenovirally transduced cells 44, 45 which might have anti-apoptotic effects on the axotomized neurons. This cytokine production may in turn be responsible for the MCMV promoter shutdown. 46 In any case, the neuroprotective effects of the 'null' vectors have to be considered in further experiments using adenoviral transduction in the brain since the effects of potential therapeutic transgenes might easily be overestimated. The usage of gutless adenoviral vectors, which do not carry any adenoviral genes, will be helpful in evaluating the mechanismns underlying the observed neuroprotective effects.
The low number of ␤-galactosidase-positive RGCs 5 days after Ad.lacZ administration is in accordance with the findings of others 47 who showed that no ␤-galactosidase-positive signal could be detected in the retina 3 days after transduction of the superior colliculi, because of insufficient protein production. Since apoptosis kills axotomized RGCs at significant amounts around days 5-7 after axotomy 19 it may not be possible to achieve an absolute quantification of transduction in this system at all, because the reporter vector does not carry an additional neuroprotective transgene. The large number of only weakly stained cells 5 days after transduction led us to conclude that we have not detected all transduced cells by this method. In addition, the Ad.lacZ used had an HCMV promoter which may not have the same expression kinetics as the MCMV promoters in the Ad.p35 and Ad.crmA vectors. However, using an Ad.EGFP with EGFP expression driven by an MCMV promoter resulted in even fewer RGCs positive for the transgene (not shown). This indicates that after vector application at the nerve stump and short-term expression, quantitative detection of reporter genes in the whole mount retina seems to be difficult. Optimized expression cassettes including introns for higher translation levels may circumvent this problem. A more accurate and quantitative estimation of the general efficiency of cell rescue will be obtained with more elaborate vectors carrying both a reporter gene and the therapeutic gene, the former preferentially under control of a cellular, not down-regulated promoter.
Finally, it has to be noted that gene transfer in this system was accomplished by a short exposure of the axon stump to viral particles which, nevertheless, accounts for the survival of several hundred cells/mm 2 through the action of a cytoplasmic protein, p35. Thus, we would consider the efficiency of this system to be high, although we cannot yet definitely quantify how many of the transduced cells survive. However, surviving RGCs can easily be counted, allowing comparison of different transgenes for their capability to inhibit neuronal secondary cell death after axotomy. This may lead to the development of an effective gene delivery strategy after axonal lesions, eg after traumatic injuries, and will also help to dissect the pathways leading to cell death in axotomized neurons in vivo.
Furthermore, it is possible to graft a peripheral nerve to the axotomized optic nerve stump to provide a permissive substrate for regeneration of axons. The delivery of both anti-apoptotic and regeneration promoting factors (such as Gap43) from the same vector might be useful in determining the necessary components for axonal regeneration.
Materials and methods
Construction of recombinant adenoviral vectors
Recombinant adenoviral vectors were constructed by homologous recombination in 293 cells according to standard protocols. 48 The pBHGE3 backbone plasmid and the pMH4 shuttle plasmid were used. The pMH4 plasmid contains the short version (530 bp) of the murine cytomegalovirus (MCMV) promoter. The HA-tagged p35 and crmA cDNAs were cloned into pMH4 by incorporating the tag by PCR. Integrity of the resulting clones was confirmed by sequencing. pMH4 without an insert was used to generate the control vector Ad.mcmv. The control vector Ad.dE1 was made by homologous recombination between BHGE3 and the pdE1sp1A shuttle plasmid. The Ad.lacZ vector was recombined from BHGE3 and the pHCMVsp1lacZ plasmid (Microbix, Ontario, Canada). Recombinant virus was grown in suspension culture, purified and concentrated by two rounds of CsCl density gradient centrifugation and titers of transducing particles were determined by plaque assay. The amount of replication competent adenovirus (RCA) in the purified preparations was determined by a quantitative PCR approach, using primers as described before. 49 Serial dilutions of wtAd2 DNA (Sigma, Deisenhofen, Germany), mixed with 50 ng of DNA extracted from each recombinant virus, served as internal standard for quantification in the PCR process. If RCA was detectable it was found to be at least six orders of magnitude below the titers for recombinant vectors.
Control of expression
Detection of expression in transduced retinas was confirmed by RT-PCR. Total RNA was extracted from control eyes and from retinas transduced for either 7 or 14 days with the respective recombinant virus, using the RNeasy kit (Qiagen, Hilden, Germany). Two eyes per group were used and the RNA was pooled before analysis. For positive controls, RNA was extracted from MRC-5 cells transduced with either Ad.p35 or Ad.crmA. The RNA was spectrophotometrically quantified. 1 g of RNA was digested with DNase and was then reverse transcribed with a p35-specific primer (5Ј-cggcaatattaaactctgcacaaactcttc-3Ј) or a crmA-specific primer (5Ј-ttatacgagcctgttaccttaaacttg-3Ј) using Superscript reverse transcriptase (Life Technologies, Karlsruhe, Germany). Each reaction also contained a G3PDH-specific reverse transcription primer, 5Ј-ccacggccatcacgccacagctttc-3Ј. Ten pmoles of the p35 and crmA rt primers and 1 pmole of the G3PDH rt primer were used in the reverse transcriptions.
Nested PCRs were performed with the following primers: p35, first amplification: (5Ј-tcaaatggatggattccacg-3Ј) and (5Ј-ccatcaaactgcacactgtc-3Ј), second amplification: (5Ј-tgaacactattcggtaagttgc-3Ј) and (5Ј-gacgtcgtactcgta aagtcc-3Ј); crmA, first amplification: (5Ј-actgaggggaaaattaatcc-3Ј) and (5Ј-agcatccatagagtcacacc-3Ј), second amplification: (5Ј-gaaccattgtctccagatacc-3Ј) and (5Ј-tgtctggaagaattaccacc-3Ј), G3PDH, first amplification: (5Ј-cac ggcaagttcaatg-3Ј) and (5Ј-tctgagtggcagtgatg-3Ј), second amplification: (5Ј-gtgatgctggtgctga-3Ј) and (5Ј-gctaa gcagttggtgg-3Ј). Each 50 l PCR reaction contained 20 pmoles of the p35 and crmA primers and 0.2 pmoles and 2 pmoles of G3PDH primers for the first and second amplification, respectively. Cycling was performed with The RT-PCR fragments were confirmed to be p35 and crmA specific by Southern blot analysis. Aliquots from positive control reactions and from transduced retina reactions were blotted on to nylon membrane and hybridized to digoxigenin-labeled oligonucleotides (p35: 5Ј-acgtagtagtcgttgcgttc-3Ј, crmA: 5Ј-cgttggagatacgtaaaa-3Ј). Hybridization and chemiluminescent detection was performed according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany).
Confirmation of the translation products was accomplished by Western blotting of total protein extracts from transduced MRC-5 cells and detection of the HA tag with the Y11 anti-HA antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Briefly, cells were transduced with an MOI of 5, cultured overnight and lysed by boiling SDS lysis. Subsequently, a complete set of protease inhibitors was added and equal amounts of protein were separated by SDS-PAGE and blotted on to PVDF membrane.
Animal surgery: transsection of the optic nerve (ON), application of virus, retrograde labeling Surgery was performed as described in detail elsewhere. 20 Briefly, adult female Sprague-Dawley rats (200-250 g; purchased from Charles River, Sulzfeld, Germany) were anesthetized by intraperitoneal injection of chloral hydrate (0.42 g/kg body weight). After skin incision close to the superior orbital rim, the orbita was opened taking care to leave the supraorbital vein intact. Following subtotal resection of the lacrimal gland, the superior extraocular muscles were spread by means of a small retractor. The ON was exposed by longitudinal incision of the eye retractor muscle and the perineurium. ON transection was performed at a distance of approximately 2 mm from the posterior pole of the eye without damaging retinal blood supply. Animals with persistent retinal ischemia verified fundoscopically were not included in the study.
Viral vectors were applied to the nerve stump by placing a drop of about 5 l into the opened dura for no more than 5 min to avoid any side-effects due to a possible ischemia. The viscosity of the solution used to store the virus (PBS /10% glycerol) ensured that the solution was retained in the cavity of the opened dura. The solution containing the virus was then removed and a small piece of gel foam soaked in 2% aqueous FB was placed at the ocular stump of the ON retrogradely to label the retinal ganglion cells.
Fourteen days after ON transection, animals received an overdose of chloral hydrate, and the eyes were removed. The retinas were dissected, flat-mounted on to gelatine-coated glass slides, and fixed for 20 min in 4% paraformaldehyde (PFA) in PBS. RGCs were examined under the fluorescence microscope (Axiovert 35; Zeiss, Jena, Germany) using a DAPI filter (365/420 nm) for FB fluorescence. The number of FB-positive RGCs was determined by counting them in 12 distinct areas of 62500 m 2 each (three areas per retinal quadrant at three different eccentricities of 1/6, 1/2 and 5/6 of the retinal radius). Cell counts were performed according to a double blind protocol and by two different investigators.
Histochemical detection of ␤-galactosidase activity Retinas were excised and prepared virtually free of the vitreous body. The specimen were fixed for 5 min in 1% PFA/solution I (100 mm K 2 HPO 4 , 5 mm EGTA, 2 mm MgCl 2 , 0.02% NP40). They were then rinsed three times in excess volumes of solution I for 15 min each and stained for 24-72 h at 37°C in solution II (solution I + 10 mm K 3 Fe(CN) 6 FC, 10 mm K 4 F(CN) 6 C, 750 mg/ml X-gal).
Statistics
Data are given as mean ± standard error of the mean (s.e.m.). Statistical significance was assessed using oneway ANOVA followed by Duncan test. Statistical analysis was performed using the absolute numbers of labeled RGCs. The amount of cells surviving due to viral transduction was determined by subtracting the amount of cells surviving without therapy from the values obtained with the different vector applications. Pairwise comparisons of groups was performed by a non-parametrical analysis of independent samples and Mann-Whitney U test.
